ArticleAnnals of cardiothoracic surgery2026
Robotic chordae shortening in mitral valve repair.
Article in Annals of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cusp-level chordae shortening was largely abandoned after suboptimal durability in the sternotomy era. We postulated that the enhanced visualization and wristed instrumentation of totally endoscopic robotic mitral repair could enable precise shortening with durable hemodynamics and acceptable peri-operative risk. Methods: We retrospectively analyzed 523 consecutive degenerative mitral regurgitation (MR) repairs performed robotically at the National Taiwan University Hospital (January 2012-November 2024). Chordae shortening was used in 68 patients (13%; 46 primary, 22 adjunct) and compared with 455 contemporaneous repairs without shortening. Results: Baseline characteristics and operative times were similar [cross‑clamp 74±27 Conclusions: Robotic chordae shortening adds negligible operative time, shortens ICU and hospital stay, and delivers long-term valve competence equivalent to contemporary robotic repairs relying on chordal transfer or neochordae. Although new-onset atrial fibrillation was more frequent, other adverse events were rare. The robotic platform appears to overcome historical limitations of chordae shortening, restoring this tissue‑preserving option for anterior leaflet prolapse in degenerative mitral disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.